Physician profile
Amy Labib
NPI 1013696152
$4,370.23
in general payments reported to CMS, 2019-2025
35 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $311 · 2024: $2,704 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,370.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.01 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $456.53 | 2024-2025 | Tepezza, Evenity, Repatha |
| Lilly USA, LLC | $422.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $409.64 | 2023-2025 | |
| Cequr Corporation | $364.45 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $339.05 | 2024-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $302.79 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $179.02 | 2024-2025 | Veozah |
| Tandem Diabetes Care, INC. | $169.45 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $123.92 | 2024-2025 | Isturisa, Signifor Lar |
| Corcept Therapeutics | $110.74 | 2023-2025 | Korlym |
| Antares Pharma, INC. | $88.74 | 2024-2025 | Xyosted |
| Verity Pharmaceuticals INC. | $78.73 | 2024-2025 | Tlando |
| Mannkind Corporation | $70.42 | 2024-2025 | |
| Averitas Pharma INC. | $67.10 | 2023-2024 | Qutenza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $65.56 | 2024 | Tymlos |
| Abbvie INC. | $60.87 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $58.49 | 2024 | |
| Abbott Laboratories | $50.45 | 2025 | Freestyle Libre 3 |
| Embecta Corp. | $46.11 | 2024 | |
| Sequel Med Tech, LLC | $40.88 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $38.21 | 2024-2025 | Yorvipath |
| Ibsa Pharma INC. | $33.76 | 2024 | Licart, Tirosint, Flector |
| Vivus LLC | $31.22 | 2024 | Qsymia |
| Horizon Therapeutics Plc | $28.72 | 2023 | Tepezza |
| Echosens North America, INC. | $24.98 | 2024 | Fibroscan |
| Medtronic, INC. | $23.72 | 2025 | Minimed 780g |
| Kyowa Kirin, INC. | $20.00 | 2025 | |
| Pfizer INC. | $18.20 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $18.14 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.43 | 2024 | Jardiance |
| Amneal Pharmaceuticals LLC | $17.36 | 2024 | Unithroid |
| Esperion Therapeutics, INC. | $17.20 | 2024 | Nexletol |
| Theracosbio, LLC | $15.38 | 2024 | Brenzavvy |
| Tolmar, INC. | $13.64 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Labib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.